Chemorefractory patients at study entry: prior treatments and current status
| Patient no. . | Prior chemotherapy . | Current status . | ||
|---|---|---|---|---|
| Type . | Response . | DR/prior treatments . | ||
| 1 | R-CVP, R-CHOP → MR | PR | 6 mo | |
| FDR | PR | 2 mo | ||
| RIE | PD | NA | ||
| XRT | PD | NA | CCR 80+ mo | |
| 2 | R-CHOP → MR | CR | 11 mo | CR1 42 mo |
| R-CVP | PD | NA | CCR2 23+ mo | |
| 3 | R-CHOP | SD | NA | |
| RICE | SD | NA | ||
| R-ESHAP | PD | NA | ||
| R-Hyper-CVAD | PD | NA | CCR 60+ mo | |
| 4 | XRT | CR | 48 mo | |
| R-CHOP | CR | 9 mo | ||
| R-FND | PR | 17 mo | ||
| RICE | NR | NA | ||
| R-Hyper-CVAD | NR | NA | CCR 48+ mo | |
| 5 | R-CHOP | CR | 8 mo | |
| R-CHOP → MR | CR | 36 mo | ||
| R-ESHAP | NR | NA | ||
| R-Hyper-CVAD | NR | NA | ||
| R-GEMOX | NR | NA | CCR 26+ mo | |
| 6 | R-CHOP | CR | 12 mo | |
| R-ESHAP | NR | NR | CCR 36+ mo | |
| 7 | R-CHOP | NR | NA | |
| RICE | NR | NA | ||
| VBR | NR | NA | CCR 26+ mo | |
| 8 | R-CHOP | PR | 3 mo | |
| R-ESHAP | PR | 4 mo | Death 5 mo (GVHD) | |
| PD with cytopenia | ||||
| 9 | R-FND → IFN | CR | 24 mo | |
| FCR | NR | NA | ||
| VBR | NR | NA | ||
| Anti-CD19 immunotoxin | NR | NA | ||
| XRT | PD | NA | ||
| R-ESHAP | PD | NA | PD, death | |
| 5 mo | ||||
| 10 | FR | CR | Unknown | |
| R-FND | PD | NA | ||
| R-CHOP → MR | PR | 9 mo | ||
| RICE | NR | NA | ||
| VBR | NR | NA | ||
| R-GEMOX | NR | NA | ||
| R-Hyper-CVAD | NR | NA | CCR 22+ mo | |
| Patient no. . | Prior chemotherapy . | Current status . | ||
|---|---|---|---|---|
| Type . | Response . | DR/prior treatments . | ||
| 1 | R-CVP, R-CHOP → MR | PR | 6 mo | |
| FDR | PR | 2 mo | ||
| RIE | PD | NA | ||
| XRT | PD | NA | CCR 80+ mo | |
| 2 | R-CHOP → MR | CR | 11 mo | CR1 42 mo |
| R-CVP | PD | NA | CCR2 23+ mo | |
| 3 | R-CHOP | SD | NA | |
| RICE | SD | NA | ||
| R-ESHAP | PD | NA | ||
| R-Hyper-CVAD | PD | NA | CCR 60+ mo | |
| 4 | XRT | CR | 48 mo | |
| R-CHOP | CR | 9 mo | ||
| R-FND | PR | 17 mo | ||
| RICE | NR | NA | ||
| R-Hyper-CVAD | NR | NA | CCR 48+ mo | |
| 5 | R-CHOP | CR | 8 mo | |
| R-CHOP → MR | CR | 36 mo | ||
| R-ESHAP | NR | NA | ||
| R-Hyper-CVAD | NR | NA | ||
| R-GEMOX | NR | NA | CCR 26+ mo | |
| 6 | R-CHOP | CR | 12 mo | |
| R-ESHAP | NR | NR | CCR 36+ mo | |
| 7 | R-CHOP | NR | NA | |
| RICE | NR | NA | ||
| VBR | NR | NA | CCR 26+ mo | |
| 8 | R-CHOP | PR | 3 mo | |
| R-ESHAP | PR | 4 mo | Death 5 mo (GVHD) | |
| PD with cytopenia | ||||
| 9 | R-FND → IFN | CR | 24 mo | |
| FCR | NR | NA | ||
| VBR | NR | NA | ||
| Anti-CD19 immunotoxin | NR | NA | ||
| XRT | PD | NA | ||
| R-ESHAP | PD | NA | PD, death | |
| 5 mo | ||||
| 10 | FR | CR | Unknown | |
| R-FND | PD | NA | ||
| R-CHOP → MR | PR | 9 mo | ||
| RICE | NR | NA | ||
| VBR | NR | NA | ||
| R-GEMOX | NR | NA | ||
| R-Hyper-CVAD | NR | NA | CCR 22+ mo | |
DR indicates duration of response; R, rituximab; CVP, cyclophosphamide, vincristine, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; MR, maintenance rituximab; PR, partial remission; FDR, fludarabine, dexamethasone, rituximab; RIE, rituximab, ifosfamide, etoposide; PD, progressive disease; NA, not applicable; XRT, involved-field radiation therapy; CCR, continuous complete remission; SD, stable disease; ICE, ifosfamide, carboplatin, and etoposide; ESHAP, etoposide, cisplatin, cytarabine, and methylprednisolone; Hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; FND, fludarabine, mitoxantrone, and dexamethasone; F, fludarabine; GEMOX, gemcitabine and oxaliplatin; and VB, bortezomib and bendamustine.